The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

9 Nov 2016 09:36

RNS Number : 7388O
Diurnal Group PLC
09 November 2016
 

9 November 2016

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations.

 

On 8 November 2016 the following par value options over ordinary shares of 5 pence in Diurnal were granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total no. of shares under award

Type of awards

Martin Whitaker

133,333

Performance Share Award

Martin Whitaker

69,565

Deferred Bonus Award

Ian Ardill

81,250

Performance Share Award

Ian Ardill

22,608

Deferred Bonus Award

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date.

 

The deferred bonus awards will ordinarily vest on the first anniversary of their grant subject to the grantee's continued service.

 

The awards were granted under award agreements that incorporated the terms of the Plan and comprised a mix of tax-favoured 'EMI' awards and non-tax favoured awards.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

Details of the full notifications received by the Company are set out below:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Martin Whitaker

2

Reason for Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Diurnal Group plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each in Diurnal Group plc

GB00BDB6Q760

b)

Nature of the transaction

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Non-EMI performance share award over 133,333 ordinary shares.

 

EMI deferred bonus award over 9,730 ordinary shares.

 

Non-EMI deferred bonus award over 59,835 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

The deferred bonus awards will ordinarily vest on the first anniversary of their grant subject to continued service.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

133,333

Nil

9,730

Nil

59,835

d)

Aggregated information

- Aggregated volume

- Price

Award over total of 202,898 ordinary shares. Nil price payable for grant.

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ian Ardill

2

Reason for Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Diurnal Group plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each in Diurnal Group plc

GB00BDB6Q760

b)

Nature of the transaction

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

EMI performance share award over 53,323 ordinary shares.

 

Non-EMI performance share award over 27,927 ordinary shares.

 

EMI deferred bonus award over 22,608 ordinary shares.

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date.

 

The deferred bonus award will ordinarily vest on the first anniversary of its grant subject to continued service.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

53,323

Nil

27,927

Nil

22,608

d)

Aggregated information

- Aggregated volume

- Price

Award over total of 103,858 ordinary shares. Nil price payable for grant.

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

Outside a trading venue

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFSMSUUFMSEDF
Date   Source Headline
12th May 20213:44 pmRNSDirector Dealings
12th May 20211:58 pmRNSHolding(s) in Company
12th May 202112:08 pmRNSHolding(s) in Company
12th May 20217:00 amRNSAgreement with Citrine Medicine for Efmody
11th May 20214:43 pmRNSHolding(s) in Company
11th May 20213:25 pmRNSHolding(s) in Company
10th May 202110:26 amRNSResult of General Meeting
23rd Apr 20217:00 amRNSGrant of second European Patent for Alkindi
21st Apr 202111:51 amRNSResult of Placing and Subscription
21st Apr 20217:00 amRNSProposed Placing, Subscription and Open Offer
15th Apr 20219:49 amRNSRequest for Efmody Orphan Designation withdrawn
26th Mar 20212:06 pmRNSSecond Price Monitoring Extn
26th Mar 20212:00 pmRNSPrice Monitoring Extension
26th Mar 202111:57 amRNSEMA issues positive opinion for second product
15th Mar 20217:00 amEQSEdison Investment Research Limited: Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders
10th Mar 20219:44 amRNSHolding(s) in Company
8th Mar 20215:34 pmRNSHolding(s) in Company
25th Feb 20217:15 amEQSHardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)
24th Feb 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
23rd Feb 20217:01 amRNSInterim Results
23rd Feb 20217:00 amRNSChronocort agreement with Consilient for Nordics
2nd Feb 20217:01 amRNSChronocort results published in JCEM
27th Jan 20219:00 amRNSPrice Monitoring Extension
27th Jan 20217:00 amRNSChina licencing agreement with Citrine for Alkindi
14th Jan 20217:01 amRNSBusiness and trading update
14th Jan 20217:00 amRNSAgreement with Eton for Alkindi extended to Canada
13th Jan 202110:07 amRNSAgreement with Er-Kim for distribution in Turkey
12th Jan 20217:00 amRNSChronocort MAA Submitted to the UK MHRA
11th Jan 20217:00 amRNSGrant of European Patent for Chronocort
22nd Dec 20203:29 pmRNSIssue of LTIP Awards
11th Dec 20202:02 pmRNSExercise of Options, Issue of Equity and TVR
23rd Nov 20207:00 amRNSExercise of Options, Issue of Equity and TVR
20th Nov 202012:06 pmRNSResult of Annual General Meeting
20th Nov 20207:00 amRNSGrant of European Patent for Alkindi
10th Nov 20207:00 amRNSNotice of Interim Results
2nd Nov 20204:47 pmRNSHolding(s) in Company
30th Oct 202011:34 amRNSHolding(s) in Company
30th Oct 20208:37 amRNSHolding(s) in Company
29th Oct 202010:30 amRNSHolding(s) in Company
29th Oct 20209:25 amRNSDirector Dealings
28th Oct 202012:49 pmRNSResult of General Meeting and Open Offer
21st Oct 20207:00 amRNSMAA for Alkindi submitted to Swissmedic
19th Oct 20207:00 amRNSVesting of LTIP awards
9th Oct 202010:37 amRNSResult of Placing, Open Offer and Notice of GM
9th Oct 20207:00 amRNSProposed Placing and Open Offer
8th Oct 20202:28 pmRNSPosting of Annual Report and AGM Notice
30th Sep 20204:41 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20208:15 amEQSHardman & Co Research: Diurnal (DNL): And then there were three
30th Sep 20207:00 amRNSAlkindi Sprinkle approved by US FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.